Your browser doesn't support javascript.
Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy.
Rico, Audrey; Ninove, Laetitia; Maarouf, Adil; Boutiere, Clémence; Durozard, Pierre; Demortiere, Sarah; Saba Villarroel, Paola Mariela; Amroun, Abdennour; Fourié, Toscane; de Lamballerie, Xavier; Pelletier, Jean; Audoin, Bertrand.
  • Rico A; Department of Neurology, Aix-Marseille University, University Hospital of Marseille, Marseille, France.
  • Ninove L; Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
  • Maarouf A; Department of Neurology, Aix-Marseille University, University Hospital of Marseille, Marseille, France.
  • Boutiere C; Department of Neurology, Aix-Marseille University, University Hospital of Marseille, Marseille, France.
  • Durozard P; Department of Neurology, Aix-Marseille University, University Hospital of Marseille, Marseille, France.
  • Demortiere S; Department of Neurology, Aix-Marseille University, University Hospital of Marseille, Marseille, France.
  • Saba Villarroel PM; Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
  • Amroun A; Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
  • Fourié T; Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
  • de Lamballerie X; Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
  • Pelletier J; Department of Neurology, Aix-Marseille University, University Hospital of Marseille, Marseille, France.
  • Audoin B; Department of Neurology, Aix-Marseille University, University Hospital of Marseille, Marseille, France.
Mult Scler J Exp Transl Clin ; 7(4): 20552173211062142, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1551174
ABSTRACT
We studied the serologic response to the BNT162b2 mRNA vaccine at four weeks after the second dose in patients with RRMS treated with rituximab with extended-interval dosing (n = 26). At four weeks, 73% of patients were seropositive. No patient without B cells at the first dose (n = 4) was seropositive. Four of seven (57%) patients with B-cell proportion >0% and ≤5% were seropositive. All patients with B-cell proportion >5% (n = 15) were seropositive. In all patients, quantitative ELISA measures after vaccination were correlated with B-cell counts measured before vaccination. In patients receiving rituximab, seropositivity after BNT162b2 mRNA vaccination emerged only after B-cell repopulation.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Mult Scler J Exp Transl Clin Year: 2021 Document Type: Article Affiliation country: 20552173211062142

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Mult Scler J Exp Transl Clin Year: 2021 Document Type: Article Affiliation country: 20552173211062142